Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 11/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.59 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823868 | 0.96 | CHRM3 (0.64) | CHRM3CHRM2CHRM1DRD2SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL2823831 | 0.92 | CHRM2 (0.57) | CHRM3CHRM2CHRM1DRD2SLC18A3 | |
| Formic Acid SCHEMBL2821390 | 0.81 | CHRM3 (0.63) | CHRM3CHRM2CHRM1 | |
| Formic Acid SCHEMBL2820095 | 0.80 | CHRM3 (0.57) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL2820620 | 0.78 | CHRM3 (0.55) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2824565 | 0.77 | CHRM3 (0.72) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2822001 | 0.76 | CHRM3 (0.68) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2820151 | 0.76 | CHRM3 (0.73) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2823765 | 0.75 | CHRM3 (0.62) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2824518 | 0.74 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519933-B1 | QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL SA (ES) | 2010-05-12 | — | — | EP | claimed |
| US-7488735-B2 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-10 | — | — | US | claimed |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | ALMIRALL AG | 2008-09-25 | — | — | US | claimed |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| US-7718670-B2 | Quinuclidine amide derivatives | LABORATORIOS ALMIRALL S.A (ES) | 2010-05-18 | — | — | US | disclosed |
| EP-1519933-B1 | QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL SA (ES) | 2010-05-12 | — | — | EP | disclosed |
| US-7488735-B2 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-10 | — | — | US | disclosed |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | ALMIRALL AG | 2008-09-25 | — | — | US | disclosed |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
| EP-1519933-A1 | QUINUCLIDINE AMIDE DERIVATIVES | Almirall Prodesfarma AG (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005285-A1 | NEW QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234316-A1 | Quinuclidine Amide Derivatives | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.